Drug Trial News

RSS

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint.

11 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients.

9 Feb 2015

Abiraterone drug improves survival in prostate cancer patients when given before chemotherapy

Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown.

9 Feb 2015

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.

8 Feb 2015

BAI-led #KnowBetterDoBetter movement comes to Broward County to eliminate HIV/AIDS

The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Broward County and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.

6 Feb 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®.

From COOK MEDICAL INC. 4 Feb 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol.

4 Feb 2015

Preliminary research supports alternative drug for treating neonatal abstinence syndrome

In the past decade, the number of Kentucky babies starting life with a drug dependency, or neonatal abstinence syndrome (NAS), has skyrocketed from 1.3 per 1,000 births to 19 per 1,000 births.

4 Feb 2015

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).

4 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.

3 Feb 2015

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Feb 2015

Bionomics initiates BNC210 Phase 1b clinical trial in healthy volunteers

Bionomics Limited has initiated a Phase 1b clinical trial in healthy volunteers of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

2 Feb 2015

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.

2 Feb 2015

Scientists discover hidden mechanism which could explain why some cancer therapies fail trials

Scientists based at the University of Helsinki, Finland, have discovered a 'hidden' mechanism which could explain why some cancer therapies which aim to block tumour blood vessel growth are failing cancer trials.

31 Jan 2015

Drug Trial News

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Abiraterone drug improves survival in prostate cancer patients when given before chemotherapy

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

BAI-led #KnowBetterDoBetter movement comes to Broward County to eliminate HIV/AIDS

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Preliminary research supports alternative drug for treating neonatal abstinence syndrome

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

Bionomics initiates BNC210 Phase 1b clinical trial in healthy volunteers

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

Scientists discover hidden mechanism which could explain why some cancer therapies fail trials

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News